Table 4.
Subset analyses on tumor control in patients with locoregionally advanced NPC treated by NAC plus IMRT vs. CCRT plus AC
| Stage | OS | LRRFS | DMFS | DFS | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Overall | 1.14 (0.70–1.87) | 0.599 | 1.27 (0.62–2.59) | 0.515 | 1.22 (0.72–2.08) | 0.456 | 1.16 (0.74–1.81) | 0.517 |
| III | 1.52 (0.68–3.39) | 0.308 | 2.23 (0.79–6.24) | 0.119 | 1.62 (0.69–3.80) | 0.259 | 1.62 (0.83–3.16) | 0.155 |
| IV | 1.04 (0.55–1.96) | 0.912 | 0.65 (0.21–1.98) | 0.440 | 1.11 (0.55–2.21) | 0.777 | 0.92 (0.50–1.70) | 0.789 |
| T1–2 | 0.70 (0.14–3.48) | 0.663 | 50.52 (0–6.22 × 108) | 0.386 | 0.48 (0.11–2.17) | 0.332 | 0.65 (0.16–2.60) | 0.537 |
| T3–4 | 1.23 (0.73–2.07) | 0.430 | 1.25 (0.61–2.57) | 0.548 | 1.41 (0.80–2.49) | 0.237 | 1.27 (0.79–2.02) | 0.325 |
| N0–1 | 1.17 (0.60–2.28) | 0.638 | 1.38 (0.55–3.47) | 0.487 | 1.12 (0.54–2.32) | 0.766 | 1.08 (0.60–1.94) | 0.797 |
| N2–3 | 1.11 (0.52–2.37) | 0.783 | 1.01 (0.31–3.30) | 0.990 | 1.42 (0.66–3.07) | 0.370 | 1.27 (0.64–2.52) | 0.487 |
OS overall survival, LRRFS locoregional relapse-free survival, DMFS distant metastasis-free survival, DFS disease-free survival, HR hazard ratio, CI confidence interval. Other abbreviations as in Table 1